Double-blind, randomized, placebo-controlled clinical study to evaluate efficacy and safety of Yestimun® in subjects with increased susceptibility to common cold

eiber GmbH (Germany)0 个研究点目标入组 224 人开始时间: 2012年8月3日最近更新: 2016年11月7日

适应症

试验速览

暂无简介。

•1. Age: = 18 years (child-bearing females had to agree to use appropriate birth control methods)
•2. At least three common cold infections within the last six months
•3. Written consent of the subject to study participation, subject understands the requirements and is willing to comply

•1. Acute infection of the upper airways (e.g. acute bronchitis)
•2. Chronic upper airway disease (e.g. chronic bronchitis, tonsillitis or asthma)
•3. Chronic cough of any origin
•4. Chronic rhinitis (vasomotor or allergic rhinitis)
•5. Congenital or acquired immunodeficiency disease (e.g. HIV infection)
•6. Acute or chronic diarrhea
•7. Severe organ or systemic diseases
•8. Suspected swine flu or influenza
•9. Body temperature above 37.5°C
•10. Vaccination against influenza or swine flu within 21 days prior to study start
•11. Known hypersensitivity to ingredients of the investigational product
•12. Pregnancy and lactation
•13. Use of immunosuppressants
•14. Use of immunostimulants (e.g. Echinacea) within the last 14 days prior to study start
•15. Use of antibiotics within the last 14 days prior to study start
•16. Alcohol/drug abuse; drug addiction
•17. Simultaneous participation in another clinical trial or participation in a clinical trial within the last 4 weeks
•18. Regular use of other yeast preparations
•19. Incertainty regarding compliance

发起方

eiber GmbH (Germany)